Introduction
Recommendations of health care providers have been shown to increase vaccine uptake, with quality of the recommendation positively associated with vaccination\(^1\)\(^-\)\(^3\). Less is known about the role of other health care staff in promoting vaccine uptake. During an office visit, a patient may encounter a receptionist, nurse, physician, laboratory or radiology technician, as well as a pharmacist after the visit. Studies have shown lower rates of COVID-19 vaccination among nurses and aides compared to physicians\(^4\), and variation in their trusted sources of vaccine information\(^5\). We examined COVID-19 vaccine concerns among a range of health care providers and ancillary staff and assessed reported vaccination of their adolescent children and intent to vaccinate younger children as part of an effort to improve pediatric COVID-19 vaccine uptake.

Methods
The study took place November 1st–December 27th, 2021 at an integrated health system with approximately 15 hospitals and 235 clinics. A web-based survey was widely distributed by organizational leaders to cascade to health care providers and ancillary staff to assess intent to vaccinate their children against COVID-19 and concerns regarding vaccination. Respondents were categorized as physicians, advanced practice providers, pharmacists, nurses, and other personnel (administrative personnel, laboratory personnel and imaging personnel). The study was approved by the Institutional Review Board, and all participants gave informed consent.

Results
Of 1883 total respondents, 1437 had children and were eligible to participate in the survey. Of these, 46% were physicians, 2% advanced practice providers, 39% nurses, 3% pharmacists, and 10% other personnel. Most providers reported receiving a pediatrician recommendation for their adolescent to be vaccinated (physician 52%, pharmacist 55%, nurse 61%, and other personnel 48%) (Table 1). Physicians and pharmacists reported higher vaccination of their children 12–17 years old (91%) compared to 61% of nurses and 59% of other personnel (p < 0.001). Physicians and pharmacists also reported higher intention to vaccinate their children 5-11 years old (80% and 75%, respectively) compared to 39% of nurses and 38% of other personnel (p < 0.001). Concerns about COVID-19 vaccines were more commonly reported by nurses and other personnel than physicians and pharmacists (Table 2); for example, more than twice as many nurses and other personnel reported concerns about allergic reactions and infertility compared to physicians and pharmacists, closely followed by concerns about the vaccines being too new and the perception that children do not need the vaccine.

Discussion
Despite overall high vaccination among respondents (92%) and no differences by provider/staff type for receipt of a pediatrician recommendation, fewer nurses and other personnel versus physicians and pharmacists reported vaccination of their adolescents and intention to vaccinate their younger children. Concerns about COVID-19 vaccines reported by nurses and other personnel also differed significantly from concerns reported by physicians and pharmacists. While all providers and staff reported safety concerns such as myocarditis and local and systemic reactions, nurses and other personnel more frequently reported concern about anaphylaxis and infertility. Although COVID-19 disease has been shown to have adverse effects on fertility and pregnancy outcomes, COVID-19 mRNA vaccines have not been found to be associated with reduced fecundity\(^6\)\(^-\)\(^7\). A review of anaphylaxis from the Vaccine Adverse Event Reporting System (VAERS) database found a rate of approximately 2.5–4.7 per 1,000,000 doses with the mRNA COVID-19 vaccines\(^8\). In the Vaccine Safety Datalink (VSD), anaphylaxis rates after dose 2 of mRNA COVID-19 vaccine were approximately 75% lower than anaphylaxis rates after dose 1\(^9\).
### Table 1. COVID-19 vaccination perspectives and intentions among respondents with children, by provider type.

| Parents of adolescents ages 12–17 | p-value |
|-----------------------------------|---------|
| Overall N = 581 n (%)             |         |
| Physician N = 236 n (%)           |         |
| Advanced Practice Provider N = 7 n (%) |         |
| Nurse N = 255 n (%)               |         |
| Pharmacist N = 22 n (%)           |         |
| Other N = 61 n (%)                |         |
| **Pediatrician recommended respondent’s adolescent child(ren) receive a COVID-19 vaccine** |         |
| 320 (56)                          | 120 (52) | 5 (71) | 154 (61) | 12 (55) | 29 (48) | 0.2 |
| **Any of respondent’s children 12–17 years old received a COVID-19 vaccine** |         |
| 422 (74)                          | 212 (91) | 3 (43) | 153 (61) | 20 (91) | 34 (59) | <0.001 |

### Table 2. Concerns about COVID-19 vaccines for children among parents, by provider type.

| Concerns about COVID-19 vaccines | Overall N = 1436 n (%) | Physician N = 661 n (%) | Advanced Practice Provider N = 25 n (%) | Nurse N = 563 n (%) | Pharmacist N = 47 n (%) | Other N = 140 n (%) | p-value |
|----------------------------------|------------------------|--------------------------|----------------------------------------|---------------------|-------------------------|---------------------|---------|
| No concerns                      | 392 (27)               | 263 (40)                 | 2 (8.0)                                | 93 (17)             | 8 (17)                  | 26 (19)             | <0.001  |
| Safety (myocarditis, blood clots, etc.) | 844 (59)               | 320 (48)                 | 18 (72)                                | 387 (69)            | 26 (55)                 | 93 (66)             | <0.001  |
| Side effects (fever, chills, sore arm, etc.) | 494 (34)               | 187 (28)                 | 13 (52)                                | 218 (39)            | 15 (32)                 | 61 (44)             | <0.001  |
| Allergic reactions (hives, anaphylaxis, etc.) | 373 (26)               | 99 (15)                  | 11 (44)                                | 203 (36)            | 6 (13)                  | 54 (39)             | <0.001  |
| Infertility                      | 276 (19)               | 39 (6)                   | 7 (28)                                 | 186 (33)            | 2 (4)                   | 42 (30)             | <0.001  |
| Vaccine is too new               | 475 (33)               | 109 (16)                 | 8 (32)                                 | 282 (50)            | 8 (17)                  | 68 (49)             | <0.001  |
| Kids don’t need the vaccine      | 284 (20)               | 81 (12)                  | 10 (40)                                | 162 (29)            | 5 (11)                  | 26 (19)             | <0.001  |
| Long-term effects of COVID-19 vaccine | 616 (43)               | 164 (25)                 | 11 (44)                                | 343 (61)            | 22 (47)                 | 76 (54)             | <0.001  |
| Other                            | 34 (2)                 | 8 (1)                    | 0 (0)                                  | 22 (4)              | 1 (2)                   | 3 (2)               | 0.037   |

p-values from chi-square tests or Fisher exact tests, as appropriate.

Note: One respondent did not indicate their provider type and was excluded from the table above.
Limitations of this study include selection bias given the open distribution of the survey, such that respondents may not be representative of their provider/staff type. Despite this limitation, the survey is consistent with prior findings of parental concern that a COVID-19 vaccine might cause lasting health problems for their child or serious vaccine side effects and expands upon prior work to identify differences in specific concerns about pediatric COVID-19 vaccination across health care providers and ancillary staff.

These findings underscore the need for focused efforts to update ancillary staff as well as all health care providers on emerging COVID-19 vaccine safety information for children. As ancillary staff have multiple interactions with pediatric patients and their caregivers before, during, and after a visit, it is imperative that they are equipped to strengthen, rather than diminish, COVID-19 vaccine recommendations.

Bruno J. Lewin1,2✉, David Bronstein3, Julia E. Tubert2, John Chang2, Yi X. Luo2, Kristen R. Choi2,4,5, Corrine Munoz-Plaza2, June L. Rondinelli6 and Katia Bruxvoort2,7

1 Department of Family Medicine, Southern California Permanente Medical Group, Los Angeles, CA, USA. 2 Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA. 3 Department of Pediatric Infectious Disease, Southern California Permanente Medical Group, Lancaster, CA, USA. 4 School of Nursing, University of California, Los Angeles (UCLA), Los Angeles, CA, USA. 5 Department of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA, USA. 6 Department of Nursing Research, Kaiser Permanente Southern California, Pasadena, CA, USA. 7 Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA. ✉email: Bruno.j.lewin@kp.org

DATA AVAILABILITY
All data generated or analyzed during this study are included in this published article.

REFERENCES
1. Nguyen, K. H. et al. Report of health care provider recommendation for COVID-19 vaccination among adults, by recipient COVID-19 vaccination status and attitudes — United States, April–September 2021. MMWR Morb. Mortal. Wkly Rep. 70, 1723–1730 (2021).
2. Lau, M., Lin, H. & Flores, G. Factors associated with human papillomavirus vaccine series initiation and healthcare provider recommendation in US adolescent females: 2007 National Survey of Children’s Health. Vaccine 30, 3112–3118 (2012).
3. Gilkey, M. B. et al. Provider communication and HPV vaccination: the impact of recommendation quality. Vaccine 34, 1187–1192 (2016).
4. Lee, J. T. et al. Disparities in COVID-19 vaccination coverage among health care personnel working in long-term care facilities, by job category, National Healthcare Safety Network — United States, March 2021. MMWR Morb. Mortal. Wkly Rep. 70, 1036–1039 (2021).
5. Brauer, E. et al. Health care providers’ trusted sources for information about COVID-19 vaccines: mixed methods study. JMIIR Infodemiology. 1, e33330 (2021).
6. Chen, F. et al. Effects of COVID-19 and mRNA vaccines on human fertility. Hum. Reprod. 37, 5–13 (2021).
7. Wesselink A. K., et al. A prospective cohort study of COVID-19 vaccination, SARS-CoV-2 infection, and fertility. Am. J. Epidemiol. 2022. https://doi.org/10.1093/aje/kwac011
8. Shimabukuro, T. T., Cole, M. & Su, J. R. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021. JAMA 325, 1101–1102 (2021).
9. Klein, N. P. et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 326, 1390–1399 (2021).
10. Szilagyi, P. G. et al. Parents’ intentions and perceptions about COVID-19 vaccination for their children: results from a national survey. Pediatrics 148, e2021052335 (2021).

ACKNOWLEDGEMENTS
We thank the Care Improvement Research Team and clinical leaders in medicine, nursing, pharmacy, laboratory and imaging at Kaiser Permanente Southern California for supporting this study and participant recruitment. This study was funded by a grant from the Care Improvement Research Team within the Department of Research & Evaluation at Kaiser Permanente Southern California. The funder had no role in the design of the study, data collection/analysis, interpretation of data, or writing the manuscript.

AUTHOR CONTRIBUTIONS
B.J.L., D.B. and K.B. conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript. J.E.T., J.C. and Y.X.L. designed the data collection instruments, collected data, carried out the initial analyses, and reviewed and revised the manuscript. K.R.C. and J.L.R. and C.M.-P. conceptualized and designed the study, and reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

CONSENT STATEMENT
All participants gave informed consent upon starting the anonymous web-based survey.

CONFLICT OF INTEREST
Ms Tubert reports research funding from Moderna and Pfizer unrelated to this study. Dr Luo reports research funding from GlaxoSmithKline, Seqirus, Moderna, and Pfizer unrelated to this study. Dr Rondinelli reports research funding from Merck unrelated to this study. Dr Bruxvoort reports research funding from Dynavax, Gilead, GlaxoSmithKline, Seqirus, Moderna, and Pfizer unrelated to this study. The remaining authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Bruno J. Lewin.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.